3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
78
Lung Neoplasms
17
Neoplasms
14
Carcinoma
9
Neoplasm Metastasis
7
Thoracic Neoplasms
4
NSCLC
4
Colorectal Neoplasms
4
Respiratory Tract Neoplasms
3
Respiratory Tract Diseases
3
Neoplasms by Site
3
Lung Diseases
3
Bronchial Neoplasms
3
Brain Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Noonan Syndrome
2
Neoplasms, Nerve Tissue
2
Neoplasms by Histologic Type
2
Meningeal Carcinomatosis
2
Head and Neck Neoplasms
2
Carcinoma, Bronchogenic
2
Breast Neoplasms
2
Adenocarcinoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
T790M Positive NSCLC Patients
1
Stomach Neoplasms
1
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
osimertinib
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA